SRC - Wiki-MPM

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
ERBB3	erb-b2 receptor tyrosine kinase 3		Tucatinib	Lethal congenital contractural syndrome (LCCS) Type I diabetes mellitus
ERBB4	erb-b2 receptor tyrosine kinase 4		Afatinib Fostamatinib Brigatinib Zanubrutinib
ERRFI1	ERBB receptor feedback inhibitor 1
ESR1	estrogen receptor 1	Nuclear signaling by ERBB4 PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Ovarian tumor domain proteases PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors RUNX1 regulates estrogen receptor mediated transcription ESR-mediated signaling RUNX1 regulates transcription of genes involved in WNT signaling Regulation of RUNX2 expression and activity Regulation of RUNX2 expression and activity Extra-nuclear estrogen signaling Estrogen-dependent gene expression	Diethylstilbestrol Chlorotrianisene Conjugated estrogens Desogestrel Levonorgestrel Progesterone Lindane Raloxifene Toremifene Medroxyprogesterone acetate Testosterone Mitotane Estrone Tamoxifen Hexachlorophene Estradiol Ethynodiol diacetate Dobutamine Clomifene Dienestrol Fulvestrant Norgestimate Ethinylestradiol Melatonin Trilostane Naloxone Fluoxymesterone Estramustine Mestranol Danazol Oxybenzone Allylestrenol Zinc Genistein Prasterone Benzophenone Equilin Compound 19 Resveratrol Compound 18 Phthalic Acid Pyrazole Stanolone Naringenin Compound 4-D 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol Quercetin Afimoxifene 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol Estriol Estrone sulfate Quinestrol Phenolphthalein Permethrin Ospemifene AP1081 Custirsen NP-50301 CHF 4227 TAS-108 Lasofoxifene Arzoxifene Elacestrant Bazedoxifene Methyltestosterone beta-Naphthoflavone 17-METHYL-17-ALPHA-DIHYDROEQUILENIN 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL Hexestrol dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate Erteberel N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL 2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol Tibolone Eugenol Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, B Polyestradiol phosphate Norethynodrel Octocrylene Homosalate Enzacamene Zeranol Ractopamine Gestrinone Propyl Gallate 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol Testosterone cypionate Testosterone enanthate Testosterone undecanoate Stanolone acetate Estradiol acetate Estradiol benzoate Estradiol cypionate Estradiol dienanthate Estradiol valerate Zinc acetate Zinc chloride Zinc sulfate, unspecified form Estriol tripropionate Fluoroestradiol F-18
ESR2	estrogen receptor 2	PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Nuclear Receptor transcription pathway PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ESR-mediated signaling Extra-nuclear estrogen signaling	Diethylstilbestrol Conjugated estrogens Progesterone Raloxifene Estrone Tamoxifen Estradiol Trilostane Estramustine Oxybenzone Genistein Prasterone Benzophenone Phthalic Acid Pyrazole Para-Mercury-Benzenesulfonic Acid Naringenin ICI-164384 5-Alpha-Androstane-3-Beta,17beta-Diol 4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol Quercetin Afimoxifene Estriol Estrone sulfate MF101 CHF 4227 TAS-108 Lasofoxifene Arzoxifene Bazedoxifene Prinaberel ERB-196 [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE 4-(6-HYDROXY-BENZO[D]ISOXAZOL-3-YL)BENZENE-1,3-DIOL 2-(5-HYDROXY-NAPHTHALEN-1-YL)-1,3-BENZOOXAZOL-6-OL 2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL (3aS,4R,9bR)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol 1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL 4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME 5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-CARBONITRILE 3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE 3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-OL (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL 17alpha-Estriol (9aS)-4-bromo-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one Erteberel (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL Eugenol Octocrylene Enzacamene Equol 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol Estradiol acetate Estradiol benzoate Estradiol cypionate Estradiol dienanthate Estradiol valerate Estriol tripropionate Fluoroestradiol F-18
ETS1	ETS proto-oncogene 1, transcription factor	Oncogene Induced Senescence
ETS2	ETS proto-oncogene 2, transcription factor	Oncogene Induced Senescence
EVL	Enah/Vasp-like	Generation of second messenger molecules Signaling by ROBO receptors Signaling by ROBO receptors RHO GTPases Activate Formins
FANCC	FA complementation group C	Fanconi Anemia Pathway TP53 Regulates Transcription of DNA Repair Genes		Fanconi anemia
FARP2	FERM, ARH/RhoGEF and pleckstrin domain protein 2	SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
FASLG	Fas ligand	Caspase activation via Death Receptors in the presence of ligand Regulation by c-FLIP RIPK1-mediated regulated necrosis CASP8 activity is inhibited Interleukin-4 and Interleukin-13 signaling Dimerization of procaspase-8 FasL/ CD95L signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models FOXO-mediated transcription of cell death genes TNFs bind their physiological receptors		Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
FBP2	fructose-bisphosphatase 2	Gluconeogenesis
FBXO5	F-box protein 5	SCF-beta-TrCP mediated degradation of Emi1 Regulation of APC/C activators between G1/S and early anaphase Phosphorylation of Emi1 Mitotic Metaphase/Anaphase Transition G1/S-Specific Transcription
FGR	FGR proto-oncogene, Src family tyrosine kinase	FCGR activation Platelet sensitization by LDL Neutrophil degranulation FCGR3A-mediated IL10 synthesis FCGR3A-mediated phagocytosis	Dasatinib Fostamatinib Zanubrutinib
FHIT	fragile histidine triad diadenosine triphosphatase		Adenosine monotungstate Ado-P-Ch2-P-Ps-Ado	Non-small cell lung cancer Small cell lung cancer
FLNA	filamin A	Platelet degranulation GP1b-IX-V activation signalling Cell-extracellular matrix interactions RHO GTPases activate PAKs OAS antiviral response	Artenimol	Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS) Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia Periventricular nodular heterotopia (PVNH) FG syndrome (FGS); Opitz-Kaveggia syndrome
FLT3	fms related receptor tyrosine kinase 3	PI3K Cascade PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling FLT3 Signaling FLT3 Signaling STAT5 Activation FLT3 mutants bind TKIs STAT5 activation downstream of FLT3 ITD mutants KW2449-resistant FLT3 mutants semaxanib-resistant FLT3 mutants crenolanib-resistant FLT3 mutants gilteritinib-resistant FLT3 mutants lestaurtinib-resistant FLT3 mutants midostaurin-resistant FLT3 mutants pexidartinib-resistant FLT3 mutants ponatinib-resistant FLT3 mutants quizartinib-resistant FLT3 mutants sorafenib-resistant FLT3 mutants sunitinib-resistant FLT3 mutants tandutinib-resistant FLT3 mutants linifanib-resistant FLT3 mutants tamatinib-resistant FLT3 mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Negative regulation of FLT3 FLT3 signaling through SRC family kinases FLT3 signaling through SRC family kinases FLT3 signaling by CBL mutants	Sorafenib Sunitinib XL999 Tandutinib ABT-869 Lestaurtinib Midostaurin Ponatinib Nintedanib Fostamatinib Gilteritinib Brigatinib Fedratinib Amuvatinib Quizartinib Pexidartinib Pralsetinib	Acute myeloid leukemia (AML)
FOXO1	forkhead box O1	AKT phosphorylates targets in the nucleus Regulation of gene expression in beta cells AKT-mediated inactivation of FOXO1A Constitutive Signaling by AKT1 E17K in Cancer MAPK6/MAPK4 signaling Interleukin-4 and Interleukin-13 signaling Regulation of localization of FOXO transcription factors FOXO-mediated transcription of cell death genes FOXO-mediated transcription of cell death genes FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Regulation of FOXO transcriptional activity by acetylation Regulation of FOXO transcriptional activity by acetylation FOXO-mediated transcription of cell cycle genes FOXO-mediated transcription of cell cycle genes		Alveolar rhabdomyosarcoma
FRS2	fibroblast growth factor receptor substrate 2	PI3K Cascade PIP3 activates AKT signaling Frs2-mediated activation Frs2-mediated activation Constitutive Signaling by Aberrant PI3K in Cancer PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 FRS-mediated FGFR2 signaling FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 FRS-mediated FGFR4 signaling PI-3K cascade:FGFR4 Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Signaling by FGFR3 fusions in cancer Signaling by FGFR3 point mutants in cancer RET signaling Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK2 signals through FRS2 and FRS3
FYB1	FYN binding protein 1	Generation of second messenger molecules Generation of second messenger molecules Signal regulatory protein family interactions

Search Results for: SRC